Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Studies and Virtual Screening on Pyrazolopyrimidines as anti-Breast Cancer Agents

References

• Rebecca Siegel, Jiemin Ma, Zhaohui Zou, and Ahmedin Jemal, “Cancer Statistics,” CA: a Cancer Journal for Clinicians 64, no. 1 (2014): 9–29. http://doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• A. Mora, M. Taranta, N. Zaki, E. Badidi, C. Cinti, and E. Capobianco, “Ensemble Inference by Integrative Cancer Networks,” Frontiers in Genetics 5, no. 5 (2014): 59. http://doi.org/10.3389/fgene.2014.00059
   PubMedGoogle Scholar
• L. A. Renfro, M. W. An, and S. J. Mandrekar, “Precision Oncology: A New Era of Cancer Clinical Trials,” Cancer Letters 387 (2017): 121–6. https://doi.org/10.1016/j.canlet.2016.03.015
   PubMed Web of Science ®Google Scholar
• E. A. Ariazi, J. L. Ariazi, F. Cordera, and V. C. Jordan, “Estrogen Receptors as Therapeutic Targets in Breast Cancer,” Current Topics in Medicinal Chemistry 6, no. 3 (2006): 195–213. http://doi.org/10.2174/156802606776173474
   Web of Science ®Google Scholar
• G. W. Small, Y. Y. Shi, L. S. Higgins, and R. Z. Orlowski, “Mitogen-Activated Protein Kinase Phosphatase-1 is a Mediator of Breast Cancer Chemoresistance,” Cancer Research 67, no. 9 (2007): 4459–66. http://doi.org/10.1158/0008-5472.can-06-2644
   PubMed Web of Science ®Google Scholar
• C. Vicier, M. V. Dieci, and F. Andre, “New Strategies to Overcome Resistance to Mammalian Target of Rapamycin Inhibitors in Breast Cancer,” Current Opinion in Oncology 25, no. 6 (2013): 587–93. http://doi.org/10.1097/cco.0000000000000014
   PubMed Web of Science ®Google Scholar
• F. Bernstam, and F. J. Esteva, “Potential Role of Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy,” Clinical Breast Cancer 6, no. 4 (2005): 357–60. http://doi.org/10.3816/cbc.2005.n.041
   PubMedGoogle Scholar
• C. J. Watson, and K. Hughes, “Breast Cancer: The Menacing Face of Janus Kinase,” Cell Death and Differentiation 21, no. 2 (2014): 185–6. https://doi.org/10.1038/cdd.2013.170
   PubMed Web of Science ®Google Scholar
• A. M. Weaver, and C. M. Silva, “Signal Transducer and Activator of Transcription 5b: A New Target of Breast Tumor Kinase/Protein Tyrosine Kinase 6,” Breast Cancer Research : BCR 9, no. 6 (2007): R79. https://doi.org/10.1186/bcr1794
   PubMed Web of Science ®Google Scholar
• H. Masuda, D. Zhang, C. Bartholomeusz, H. Doihara, G. N. Hortobagyi, and N. T. Ueno, “Role of Epidermal Growth Factor Receptor in Breast Cancer,” Breast Cancer Research and Treatment 136, no. 2 (2012): 331–45. https://doi.org/10.1007/s10549-012-2289-9
   PubMed Web of Science ®Google Scholar
• Anon. “Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer,” Breast Cancer (2007): 235–56. http://doi.org/10.3109/9781420019940-22
   Google Scholar
• P. Giovannelli, M. Di. Donato, G. Galasso, E. Di. Zazzo, A. Bilancio, and A. Migliaccio, “The Androgen Receptor in Breast Cancer,” Frontiers in Endocrinology 9 (2018): 492. https://doi.org/10.3389/fendo.2018.00492
   PubMed Web of Science ®Google Scholar
• L. Livraghi, and J. E. Garber, “PARP Inhibitors in the Management of Breast Cancer: current Data and Future Prospects,” BMC Medicine 13, no. 1 (2015): 1–16. https://doi.org/10.1186/s12916-015-0425-1
   PubMedGoogle Scholar
• K. E. McCann, and S. A. Hurvitz, “Advances in the Use of PARP Inhibitor Therapy for Breast Cancer,” Drugs in Context 7 (2018): 212540–30. http://doi.org/10.7573/dic.212540
   PubMedGoogle Scholar
• R. L. Godone, G. M. Leitão, N. B. Araújo, C. H. M. Castelletti, J. L. Lima-Filho, and D. B. G. Martins, “Clinical and Molecular Aspects of Breast Cancer: Targets and Therapies,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 106 (2018): 14–34. https://doi.org/10.1016/j.biopha.2018.06.066
   PubMed Web of Science ®Google Scholar
• J. S. Carroll, “Mechanisms of Oestrogen Receptor (ER) Gene Regulation in Breast Cancer,” European Journal of Endocrinology 175, no. 1 (2016): R41–R49. https://doi.org/10.1530/eje-16-0124
   PubMed Web of Science ®Google Scholar
• A. Tessari, D. Palmieri, and S. Di. Cosimo, “Overview of Diagnostic/Targeted Treatment Combinations in Personalised Medicine for Breast Cancer Patients,” Pharmacogenomics and Personalized Medicine 7 (2013): 1–19. https://doi.org/10.2147/pgpm.s53304
   PubMedGoogle Scholar
• M. Kono, T. Fujii, B. Lim, M. S. Karuturi, D. Tripathy, and N. T. Ueno, “Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review,” JAMA Oncology 3, no. 9 (2017): 1266–73. https://doi.org/10.1001/jamaoncol.2016.4975
   PubMed Web of Science ®Google Scholar
• Yu Jin Kim, Jong-Sun Choi, Jinwon Seo, Ji-Young Song, Seung Eun Lee, Mi Jung Kwon, Mi Jeong Kwon, Juthika Kundu, Kyungsoo Jung, Ensel Oh, et al, “MET is a Potential Target for Use in Combination Therapy with EGFR Inhibition in Triple‐Negative/Basal‐like Breast Cancer,” International Journal of Cancer 134, no. 10 (2014): 2424–36. https://doi.org/10.1002/ijc.28566
   PubMed Web of Science ®Google Scholar
• T. Jubin, A. Kadam, M. Jariwala, S. Bhatt, S. Sutariya, A. R. Gani, S. Gautam, and R. Begum, " “The PARP Family: insights into Functional Aspects of Poly (ADP‐Ribose) Polymerase‐1 in Cell Growth and Survival,” Cell Proliferation 49, no. 4 (2016): 421–37. https://doi.org/10.1111/cpr.12268
   PubMed Web of Science ®Google Scholar
• C. Bartholomeusz, X. Xie, M. K. Pitner, K. Kondo, A. Dadbin, J. Lee, H. Saso, P. D. Smith, K. N. Dalby, and N. T. Ueno, “MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model,” Molecular Cancer Therapeutics 14, no. 12 (2015): 2773–81. https://doi.org/10.1158/1535-7163.mct-15-0243
   PubMed Web of Science ®Google Scholar
• R. L. Schroeder, C. L. Stevens, and J. Sridhar, “Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer,” Molecules (Basel, Switzerland) 19, no. 9 (2014): 15196–212. https://doi.org/10.3390/molecules190915196
   PubMed Web of Science ®Google Scholar
• Ayca Gucalp, Sara Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, Hope Rugo, Lisle Nabell, Andres Forero, Translational Breast Cancer Research Consortium (TBCRC 011), et al, “Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer,” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 19, no. 19 (2013): 5505–12. https://doi.org/10.1158/1078-0432.ccr-12-3327
   PubMed Web of Science ®Google Scholar
• L. Cortesi, H. S. Rugo, and C. Jackisch, “An Overview of PARP Inhibitors for the Treatment of Breast Cancer,” Targeted Oncology 16, no. 3 (2021): 255–82. https://doi.org/10.1007/s11523-021-00796-4
   PubMed Web of Science ®Google Scholar
• E. Cichero, and P. Fossa, “Docking-Based 3D-QSAR Analyses of Pyrazole Derivatives as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors,” Journal of Molecular Modeling 18, no. 4 (2012): 1573–82. https://doi.org/10.1007/s00894-011-1190-5
   PubMed Web of Science ®Google Scholar
• Jeanne Fichez, Cathia Soulie, Laurent Le Corre, Sophie Sayon, Stéphane Priet, Karine Alvarez, Olivier Delelis, Patrick Gizzi, Guillaume Prestat, Christine Gravier-Pelletier, et al, “Discovery, SAR Study and ADME Properties of Methyl 4-Amino-3-Cyano-1-(2-Benzyloxyphenyl)-1 H-Pyrazole-5-Carboxylate as an HIV-1 Replication Inhibitor,” RSC Medicinal Chemistry 11, no. 5 (2020): 577–82. https://doi.org/10.1039/d0md00025f
   PubMedGoogle Scholar
• A. M. K. El-Dean, A. M. Elkhawaga, S. M. Radwan, and M. M. Ahmed, “Synthesis of Some Pyridothienopyrazolopyrimidopyrimidine and Mercaptomethylpyrazolopyrimidine Derivatives,” Phosphorus, Sulfur, and Silicon 184, no. 8 (2009): 2034–48. https://doi.org/10.1080/10426500802418479
   Web of Science ®Google Scholar
• M. Ge, E. Cline, and L. Yang, “A General Method for the Preparation of 3-Acyl-4-Cyano-5-Amino-Pyrazoles,” Tetrahedron Letters 47, no. 32 (2006): 5797–9. https://doi.org/10.1016/j.tetlet.2006.05.173
   Web of Science ®Google Scholar
• H. El-Sherief, A. Mahmoud, and A. Ismaiel, “Studies on the Synthesis and Cyclisation Reactions of 2-(5-Amino-3-Arylpyrazol-1-yl)-3-Methylquinoxalines,” Journal of Chemical Research, Synopses 9(1997): 322-323. https://doi.org/10.1039/a603951k
   Google Scholar
• A. A. Aly, “Synthesis of Polyfunctionally Substituted Pyrazolonaphthyridine, Pentaazanaphthalene, and Heptaazaphenanthrene Derivatives,” Phosphorus, Sulfur, and Silicon and the Related Elements 181, no. 10 (2006): 2395–409. https://doi.org/10.1080/10426500600695179
   Web of Science ®Google Scholar
• M. Katalinić, G. Rusak, J. D. Barović, G. Šinko, D. Jelić, R. Antolović, and Z. Kovarik, “Structural Aspects of Flavonoids as Inhibitors of Human Butyrylcholinesterase,” European Journal of Medicinal Chemistry 45, no. 1 (2010): 186–92. https://doi.org/10.1016/j.ejmech.2009.09.041
   PubMed Web of Science ®Google Scholar
• B. G. Ugarkar, H. B. Cottam, P. A. McKernan, R. K. Robins, and G. R. Revankar, “Synthesis and Antiviral/Antitumor Activities of Certain Pyrazolo [3, 4-d] Pyrimidine-4 (5H)-Selone Nucleosides and Related Compounds,” Journal of Medicinal Chemistry 27, no. 8 (1984): 1026–30. https://doi.org/10.1021/jm00374a015
   PubMed Web of Science ®Google Scholar
• J. L. Rideout, T. A. Krenitsky, E. Y. Chao, G. B. Elion, R. B. Williams, and V. S. Latter, “Pyrazolo [3, 4-d] Pyrimidine Ribonucleosides as Anticoccidials. 3. Synthesis and Activity of Some Nucleosides of 4-[(Arylalkenyl) Thio] Pyrazolo [3, 4-d] Pyrimidines,” Journal of Medicinal Chemistry 26, no. 10 (1983): 1489–94. https://doi.org/10.1021/jm00364a024
   PubMed Web of Science ®Google Scholar
• A. Ali, G. E. Taylor, K. Ellsworth, G. Harris, R. Painter, L. L. Silver, and K. Young, “Novel Pyrazolo [3, 4-d] Pyrimidine-Based Inhibitors of Staphlococcus Aureus DNA Polymerase III: design, Synthesis, and Biological Evaluation,” Journal of Medicinal Chemistry 46, no. 10 (2003): 1824–30. https://doi.org/10.1021/jm020483c
   PubMed Web of Science ®Google Scholar
• Fabrizio Manetti, Annalisa Santucci, Giada A. Locatelli, Giovanni Maga, Adriano Spreafico, Tommaso Serchi, Maurizio Orlandini, Giulia Bernardini, Nicola P. Caradonna, Andrea Spallarossa, et al, “Identification of a Novel Pyrazolo [3, 4-d] Pyrimidine Able to Inhibit Cell Proliferation of a Human Osteogenic Sarcoma in Vitro and in a Xenograft Model in Mice,” Journal of Medicinal Chemistry 50, no. 23 (2007): 5579–88. https://doi.org/10.1021/jm061449r
   PubMed Web of Science ®Google Scholar
• C. R. Petrie, III, H. B. Cottam, P. A. McKernan, R. K. Robins, and G. R. Revankar, “Synthesis and Biological Activity of 6-Azacadeguomycin and Certain 3, 4, 6-Trisubstituted Pyrazolo [3, 4-d] Pyrimidine Ribonucleosides,” Journal of Medicinal Chemistry 28, no. 8 (1985): 1010–6. https://doi.org/10.1021/jm00146a007
   PubMed Web of Science ®Google Scholar
• P. H. Hutson, E. N. Finger, B. C. Magliaro, S. M. Smith, A. Converso, P. E. Sanderson, D. Mullins, L. A. Hyde, B. K. Eschle, Z. Turnbull, et al, “The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 (6-[(3S, 4S)-4-Methyl-1-(Pyrimidin-2-Ylmethyl) Pyrrolidin-3-yl]-1-(Tetrahydro-2H-Pyran-4-yl)-1, 5-Dihydro-4H-Pyrazolo [3, 4-d] Pyrimidin-4-One) Enhances Synaptic Plasticity and Cognitive Function in Rodents,” Neuropharmacology 61, no. 4 (2011): 665–76. https://doi.org/10.1016/j.neuropharm.2011.05.009
   PubMed Web of Science ®Google Scholar
• M. M. Ghorab, F. A. Ragab, S. I. Alqasoumi, A. M. Alafeefy, and S. A. Aboulmagd, “Synthesis of Some New Pyrazolo [3, 4-d] Pyrimidine Derivatives of Expected Anticancer and Radioprotective Activity,” European Journal of Medicinal Chemistry 45, no. 1 (2010): 171–8. https://doi.org/10.1016/j.ejmech.2009.09.039
   PubMed Web of Science ®Google Scholar
• M. Amir, S. A. Javed, and H. Kumar, “Pyrimidine as Antiinflammatory Agent: A Review,” Indian Journal of Pharmaceutical Sciences 69, no. 3 (2007): 337. https://doi.org/10.4103/0250-474x.34540
   Google Scholar
• A. Trivedi, D. Dodiya, J. Surani, S. Jarsania, H. Mathukiya, N. Ravat, and V. Shah, “Facile One‐Pot Synthesis and Antimycobacterial Evaluation of Pyrazolo [3, 4‐d] Pyrimidines,” Archiv Der Pharmazie 341, no. 7 (2008): 435–9. https://doi.org/10.1002/ardp.200800027
   PubMed Web of Science ®Google Scholar
• A. Trivedi, S. Vaghasiya, B. Dholariya, D. Dodiya, and V. Shah, “Synthesis and Antimycobacterial Evaluation of Various 6-Substituted Pyrazolo [3, 4-d] Pyrimidine Derivatives,” Journal of Enzyme Inhibition and Medicinal Chemistry 25, no. 6 (2010): 893–9. https://doi.org/10.3109/14756360903540276
   PubMed Web of Science ®Google Scholar
• S. Guccione, M. Modica, J. Longmore, D. Shaw, G. U. Barretta, A. Santagati, M. Santagati, and F. Russo, “Synthesis and NK-2 Antagonist Effect of 1, 6-Diphenyl-Pyrazolo [3, 4-d]-Thiazolo [3, 2-a] 4H-Pyrimidin-4-One,” Bioorganic & Medicinal Chemistry Letters 6, no. 1 (1996): 59–64. https://doi.org/10.1016/0960-894x(95)00558-b
   Web of Science ®Google Scholar
• Y. Xia, S. Chackalamannil, M. Czarniecki, H. Tsai, H. Vaccaro, R. Cleven, J. Cook, A. Fawzi, R. Watkins, and H. Zhang, “Synthesis and Evaluation of Polycyclic Pyrazolo [3, 4-d] Pyrimidines as PDE1 and PDE5 cGMP Phosphodiesterase Inhibitors,” Journal of Medicinal Chemistry 40, no. 26 (1997): 4372–7. https://doi.org/10.1021/jm970495b
   PubMed Web of Science ®Google Scholar
• J. P. James, D. Jyothi, and S. Priya, “In Silico Screening of Phytoconstituents with Antiviral Activities against SARS-COV-2 Main Protease, Nsp12 Polymerase, and Nsp13 Helicase Proteins,” Letters in Drug Design & Discovery 18, no. 8 (2021): 841–57. http://doi.org/10.2174/1570180818666210317162502
   Web of Science ®Google Scholar
• J. P. James, P. Kumar, A. Kumar, K. I. Bhat, and C. S. Shastry, “In Silico Anticancer Evaluation, Molecular Docking and Pharmacophore Modeling of Flavonoids against Various Cancer Targets,” Letters in Drug Design & Discovery 17, no. 12 (2020): 1485–501. https://doi.org/10.2174/1570180817999200730164222
   Web of Science ®Google Scholar
• Jainey P. James, Apoorva, Shreya Renita Monteiro, K. B. Sukesh, and A. Varun, “Design and Identification of Lead Compounds Targeting Nipah G Attachment Glycoprotein by in Silico Approaches,” Journal of Pharmaceutical Research International 33, no. 40A (2021): 156–69. doi: 10.9734/jpri/2021/v33i40A32232
   Web of Science ®Google Scholar
• G. S. Hassan, H. H. Kadry, S. M. Seri, M. M. Ali, and A. E. Mahmoud, “Synthesis and in Vitro Cytotoxic Activity of Novel Pyrazolo[3,4-d]Pyrimidines and Related Pyrazole Hydrazones toward Breast Adenocarcinoma MCF-7 Cell Line,” Bioorganic & Medicinal Chemistry 19, no. 22 (2011): 6808–17. https://doi.org/10.1016/j.bmc.2011.09.036
   PubMed Web of Science ®Google Scholar
• K. R. Abdellatif, E. K. Abdelall, M. A. Abdelgawad, R. R. Ahmed, and R. B. Bakr, “Synthesis and Anticancer Activity of Some New Pyrazolo[3,4-d]Pyrimidin-4-One Derivatives,” Molecules (Basel, Switzerland) 19, no. 3 (2014): 3297–309. http://doi.org/10.3390/molecules19033297
   PubMed Web of Science ®Google Scholar
• A. E. Rashad, H. A. Shamroukh, D. A. A. Osman, S. T. Gaballah, A. I. Hashem, H. S. Ali, and F. M. E. Abdel-Megeid, “Synthesis and Anticancer Evaluation of Some Fused Pyrazolopyrimidines and Their S-Acyclic Nucleosides,” Der Pharma Chemica 7, no. 5 (2015): 243–50.
   Google Scholar
• A. H. Shamroukh, A. E. Rashad, R. E. Abdel-Megeid, H. S. Ali, and M. M. Ali, “Some Pyrazole and Pyrazolo[3,4-d]Pyrimidine Derivatives: synthesis and Anticancer Evaluation,” Archiv Der Pharmazie 347, no. 8 (2014): 559–65.
   PubMed Web of Science ®Google Scholar
• E. Harder, W. Damm, J. Maple, C. Wu, M. Reboul, J. Y. Xiang, L. Wang, D. Lupyan, M. K. Dahlgren, J. L. Knight, et al, “OPLS3: A Force Field Providing Broad Coverage of Druglike Small Molecules and Proteins,” Journal of Chemical Theory and Computation 12, no. 1 (2016): 281–96. https://doi.org/10.1021/acs.jctc.5b00864
   PubMed Web of Science ®Google Scholar
• S. L. Dixon, A. M. Smondyrev, E. H. Knoll, S. N. Rao, D. E. Shaw, and R. A. Friesner, “PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening: 1. Methodology and Preliminary Results,” Journal of Computer-Aided Molecular Design 20, no. 10-11 (2006): 647–71. https://doi.org/10.1007/s10822-006-9087-6
   PubMed Web of Science ®Google Scholar
• M. K. Hamid, M. D. Mihovilovic, and H. B. El-Nassan, “Synthesis of Novel Pyrazolo [3, 4-d] Pyrimidine Derivatives as Potential anti-Breast Cancer Agents,” European Journal of Medicinal Chemistry 57 (2012): 323–8. https://doi.org/10.1016/j.ejmech.2012.09.031
   PubMed Web of Science ®Google Scholar
• Kevin D. Dykstra, Liangqin Guo, Elizabeth T. Birzin, Wanda Chan, Yi Tien Yang, Edward C. Hayes, Carolyn A. DaSilva, Lee-Yuh Pai, Ralph T. Mosley, Bryan Kraker, et al, “Estrogen Receptor Ligands. Part 16: 2-Aryl Indoles as Highly Subtype Selective Ligands for Erα,” Bioorganic & Medicinal Chemistry Letters 17, no. 8 (2007): 2322–8. https://doi.org/10.1016/j.bmcl.2007.01.054
   PubMed Web of Science ®Google Scholar
• I. Petit-Topin, M. Fay, M. Resche-Rigon, A. Ulmann, E. Gainer, M. E. Rafestin-Oblin, and J. Fagart, “Molecular Determinants of the Recognition of Ulipristal Acetate by Oxo-Steroid Receptors,” The Journal of Steroid Biochemistry and Molecular Biology 144 (2014): 427–35. https://doi.org/10.1016/j.jsbmb.2014.08.008
   PubMed Web of Science ®Google Scholar
• Y. Yosaatmadja, C. J. Squire, M. McKeage, J. U. Flanagan, "1.85 Angstrom Structure of EGFR Kinase Domain with Gefitinib” (2014). https://doi.org/10.2210/pdb4WKQ/pdb
   Google Scholar
• A. M. März, A. K. Fabian, C. Kozany, A. Bracher, and F. Hausch, “Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin,” Molecular and Cellular Biology 33, no. 7 (2013): 1357–67. https://doi.org/10.1128/mcb.00678-12
   PubMed Web of Science ®Google Scholar
• R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin, and D. T. Mainz, “Extra Precision Glide: docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes,” Journal of Medicinal Chemistry 49, no. 21 (2006): 6177–96. https://doi.org/10.1021/jm051256o
   PubMed Web of Science ®Google Scholar
• M. P. Jacobson, D. L. Pincus, C. S. Rapp, T. J. F. Day, B. Honig, D. E. Shaw, and R. A. Friesner, “Hierarchical Approach to All-Atom Protein Loop Prediction,” Proteins 55, no. 2 (2004): 351–67. https://doi.org/10.1002/prot.10613
   PubMed Web of Science ®Google Scholar
• Z. Guo, U. Mohanty, J. Noehre, T. K. Sawyer, W. Sherman, and G. Krilov, “Probing the α-Helical Structural Stability of Stapled p53 Peptides: molecular Dynamics Simulations and Analysis,” Chemical Biology & Drug Design 75, no. 4 (2010): 348–59. https://doi.org/10.1111/j.1747-0285.2010.00951.x
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2021-4: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2021. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2021.
   Google Scholar
• M. Sivashanmugam, K. N. Sulochana, and V. Umashankar, “Virtual Screening of Natural Inhibitors Targeting Ornithine Decarboxylase with Pharmacophore Scaffolding of DFMO and Validation by Molecular Dynamics Simulation Studies,” Journal of Biomolecular Structure & Dynamics 37, no. 3 (2019): 766–80. https://doi.org/10.1080/07391102.2018.1439772
   PubMed Web of Science ®Google Scholar
• C. Stork, J. Wagner, N. O. Friedrich, C. B. Kops, M. Sicho, and J. Kirchmair, “Hit Dexter: A Machine-Learning Model for the Prediction of Frequent Hitters,” ChemMedChem 13, no. 6 (2018): 564–71.
   PubMed Web of Science ®Google Scholar
• A. Golbraikh, and A. Tropsha, “Beware of q2,” Journal of Molecular Graphics & Modelling 20, no. 4 (2002): 269–76. https://doi.org/10.1016/s1093-3263(01)00123-1
   PubMed Web of Science ®Google Scholar
• R. P. Sheridan, S. B. Singh, E. M. Fluder, and S. K. Kearsley, “Protocols for Bridging the Peptide to Nonpeptide Gap in Topological Similarity Searches,” Journal of Chemical Information and Computer Sciences 41, no. 5 (2001): 1395–406.
   PubMedGoogle Scholar
• J. Kirchmair, P. Markt, S. Distinto, G. Wolber, and T. Langer, “Evaluation of the Performance of 3D Virtual Screening Protocols: RMSD Comparisons, Enrichment Assessments, and Decoy Selection – What Can we Learn from Earlier Mistakes?,” Journal of Computer-Aided Molecular Design 22, no. 3-4 (2008): 213–28.
   PubMed Web of Science ®Google Scholar